IPP Bureau
Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
By IPP Bureau - April 02, 2026
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Middle East disruption hits thousands of global clinical trials, Phesi warns
By IPP Bureau - April 02, 2026
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy
By IPP Bureau - April 02, 2026
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
By IPP Bureau - April 01, 2026
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Rusan unveils APOSAN 3ml multi-dose pen
By IPP Bureau - April 01, 2026
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Torqur taps Lonza to power late-stage push for skin cancer therapy
By IPP Bureau - April 01, 2026
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
VLCC becomes exclusive partner to offer international laser certification exams in India
By IPP Bureau - April 01, 2026
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care
By IPP Bureau - April 01, 2026
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease
By IPP Bureau - April 01, 2026
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology
By IPP Bureau - April 01, 2026
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Merck completes acquisition of JSR Life Sciences’ chromatography business
By IPP Bureau - April 01, 2026
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
By IPP Bureau - March 31, 2026
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet
By IPP Bureau - March 31, 2026
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
Samsung Biologics scores big at 2026 CDMO Leadership Awards
By IPP Bureau - March 31, 2026
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy
By IPP Bureau - March 31, 2026
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
